Clinical trials
Cisplatin clinical trials
Below are recruiting cisplatin clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06336707RecruitingPhase 1
HS-20089 combination for advanced solid tumors
This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06332170RecruitingPhase 1
HS-20093 combination safety study for advanced solid tumors
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05764044RecruitingPhase 3
Chemo after chemoradiation for HPV-positive cervical cancer
This Phase 3 study tests whether giving additional (adjuvant) chemotherapy after standard chemoradiation can help people whose blood test still shows cancer-related HPV DNA. It may help by lowering the risk of the cervical cancer coming back in people who have a positive blood biomarker after treatment.
Manaus, AmazonasAges 18–70 - NCT06100497RecruitingPhase 2
PD-1 plus chemo for advanced head and neck cancer
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07777822RecruitingPhase 3
First-line treatment for metastatic non-squamous lung cancer with RAS mutation
This trial tests whether adding a new drug (zoldonrasib) to standard chemotherapy and immunotherapy can help people with a specific type of lung cancer. It is for those with a RAS G12D mutation and no prior treatment for metastatic disease.
Plantation, FloridaAges 18 years+ - NCT07780838RecruitingPhase 2
Combination therapy for advanced bile duct cancer with an FGFR2 change
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
Columbus, OhioAges 18 years+ - NCT06572514RecruitingPhase 1/Phase 2
Lower radiation after chemo-immunotherapy for head and neck cancer
This trial tests if giving less radiation than usual is safe and effective for certain head and neck cancers after initial treatment with chemotherapy and immunotherapy. It aims to reduce side effects while still controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06289751RecruitingPhase 2
Chemo-immunotherapy before surgery for stage IB2 cervical cancer
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
Wuhan, HubeiAges 18–70 - NCT07751341RecruitingPhase 2
New drug with chemotherapy for advanced esophageal cancer
This study tests a new drug (SHR-9839) alone or combined with standard chemotherapy and another immunotherapy drug (adebrelimab) for advanced esophageal cancer. The goal is to see if this combination helps shrink tumors or slow cancer growth better than the standard treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT05200650RecruitingPhase 1
Test gel with cisplatin injected into head and neck tumors
This trial studies an anti-cancer gel that delivers cisplatin directly into a head and neck tumor with a single injection. It mainly checks safety and side effects, and also looks for early signs that the tumor responds in people whose cancer is progressing or no longer responds to standard treatment.
JerusalemAges 18–80 - NCT05286619RecruitingPhase 2
Pembrolizumab with chemotherapy for recurrent head and neck cancer
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
Kuala LumpurAges 18 years+ - NCT05487391RecruitingPhase 3
QL1706 plus chemo after lung cancer surgery
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
ShanghaiAges 18 years+ - NCT07710885RecruitingPhase 3
Futibatinib for advanced bile duct cancer
This trial tests a new targeted therapy, futibatinib, for people with advanced or unresectable bile duct cancer who have not had prior treatment for advanced disease. It aims to see if this drug can help shrink or control the cancer.
BrisbaneAges 18 years+ - NCT04760327RecruitingPhase 2
Electrotherapy for returning gynecologic cancers
This Phase 2 study tests electrotherapy (a way to help treatment reach tumor cells) for gynecologic cancers that have come back after standard treatments were used up. You may be considered if your overall health allows anesthesia and if certain cancer spread and medical safety issues do not apply.
LjubljanaAges 18–105 - NCT07700667RecruitingPhase 2
Testing a new drug combo for advanced esophageal cancer
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
ChangchunAges 18–75 - NCT07699185RecruitingPhase 2
Immunotherapy plus chemoradiation before surgery for esophageal cancer
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
Wuhan, HubeiAges 18–75 - NCT06611345Recruiting
Tumor-treating fields with immunotherapy and chemo for bile duct cancer
This trial is testing a new combination of treatments—a wearable device that sends electric fields to the tumor area (tumor-treating fields) plus immunotherapy (durvalumab) and chemotherapy (gemcitabine/cisplatin)—for people with advanced bile duct or gallbladder cancer. It may be an option if you haven't had chemotherapy for advanced disease before.
HefeiAges 18–75 - NCT07680790RecruitingPhase 3
New drug combination for advanced egfr lung cancer
This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.
Beverly Hills, CaliforniaAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06288373RecruitingPhase 2/Phase 3
Comparing chemoimmunotherapy vs chemoradiation for advanced cervical cancer before surgery
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
Hefei, AnhuiAges 18–70 - NCT07673341RecruitingPhase 2
PET scan to predict response in bile duct cancer
This study tests whether a special PET scan (using [18F]FTT) can predict how well the standard GCD chemotherapy and immunotherapy combination will work for newly diagnosed bile duct cancer. The scan helps doctors see tumor activity before treatment.
Seattle, WashingtonAges 18 years+ - NCT06289062RecruitingPhase 2
Chemo plus camrelizumab before surgery for stage IB1 cervical cancer
This trial tests whether giving chemotherapy combined with camrelizumab (a drug that helps the immune system fight cancer) before surgery can help women with early-stage cervical cancer who want to preserve their fertility. It is for patients whose tumors show a protein called PD-L1.
Guangzhou, GuangdongAges 18–45 - NCT07668154RecruitingPhase 2
Testing SKB571 for advanced head and neck cancer
This study tests a new drug called SKB571 for people whose head and neck cancer (a type called squamous cell carcinoma) has come back or spread and cannot be surgically removed. The goal is to see if the drug is safe and effective.
ChengduAges 18–75 - NCT06675214RecruitingPhase 3
Immunotherapy with modified radiation for advanced NPC
This trial tests a new way to give radiation therapy after immunotherapy and chemotherapy for people with advanced nasopharyngeal cancer (NPC) that has partially shrunk. It aims to see if a different radiation schedule works better and has fewer side effects.
Zhuhai, GuangdongAges 18–65
Hear when a new Cisplatin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cisplatin?
- Yes. Clin2 currently lists 484 recruiting cisplatin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cisplatin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cisplatin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.